Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for navenibart (STAR-0215) in Hereditary angioedema . The expected timing is based on the latest available company guidance and may change.
ALPHA-ORBIT trial. 2/27/25- Initiated ALPHA-ORBIT Ph3 trial. Topline results in early 2027. 10/11/25- Presented ALPHA-STAR Ph1b/2 results at HAEi'25. 10/8/25- Initiated ORBIT-EXPANSE Long-Term trial. 11/6/25- Positive results from full enrollment in ALPHA-STAR reported. 11/12/25:- Final ALPHA-STAR Ph1b/2 data positive; ORBIT-EXPANSE enrolled first patient; ALPHA-ORBIT Ph3 topline remains expected early 2027.
Verification
Confirm timing and program details against the company announcement or filing.